As healthcare professionals increasingly seek non invasive approaches to pain management and tissue healing, Low Level Laser Therapy (LLLT), also known as photobiomodulation, is gaining greater clinical attention. Yet as the market expands, clinicians need technologies supported by meaningful research, consistent therapeutic principles, and reliable clinical performance.
MicroLight Corporation has spent more than three decades addressing this need. Founded in 1990, the company was established with a vision of bringing research supported Low Level Laser Therapy to the United States. MicroLight ultimately became the first company granted FDA clearance to market LLLT for adjunctive use in pain therapy. Its approach remains centered on the research supported 830 nm wavelength and a controlled therapeutic dose, providing healthcare professionals with a non invasive technology designed to complement patient care.
A Legacy Built on Research and Clinical Evidence
MicroLight’s origins trace back to founder Mike Barbour, who was introduced to the pioneering work of Dr. Toshio Ohshiro of Japan, one of the leading authorities in Low Level Laser Therapy. At the time, Barbour was training and certifying physicians in Class IV laser surgery. After studying Dr. Ohshiro’s extensive clinical research involving more than 45,000 patients, he became convinced that 830 nm technology offered an effective combination of tissue penetration and photochemical stimulation without generating heat.
That belief became the foundation for MicroLight. The company spent years working with the FDA while supporting clinical research to establish the effectiveness and safety of its technology. Before receiving FDA clearance, the MicroLight Laser was evaluated in a 36 week double blind clinical study conducted with General Motors and later in another double blind study by Baylor College of Medicine. These studies became an important part of the company’s evidence based foundation.
More than 30 years later, MicroLight continues to follow the same philosophy. Rather than competing through higher wattage or marketing driven claims, the company remains focused on wavelength, therapeutic dose, clinical research, and consistent application.
Delivering Photobiomodulation Through the Smart Laser
Low Level Laser Therapy works by delivering light at a specific wavelength and therapeutic dose to stimulate a photochemical response within cells rather than generating heat. MicroLight’s Smart Laser uses its research supported 830 nm wavelength to support the body’s natural healing processes.
The technology is designed to stimulate cellular activity and support processes associated with pain reduction, inflammation modulation, microcirculation, and tissue recovery. MicroLight emphasizes that the therapeutic effect depends on delivering the appropriate wavelength and dose within an effective therapeutic window rather than simply increasing power output.
The Smart Laser portfolio provides clinicians with flexible treatment configurations, including single paddle, double paddle, and probe options. The devices are used as adjunctive treatments for minor muscle and joint pain, arthritis discomfort, muscle spasms, stiffness, and muscle relaxation. Their non invasive nature allows them to be incorporated into a variety of clinical environments.
The technology is used by a broad range of healthcare professionals, including physicians, chiropractors, physical therapists, dentists, podiatrists, veterinarians, athletic trainers, and rehabilitation specialists. This diverse adoption reflects the versatility of photobiomodulation as an adjunctive approach within different patient care settings.
Combining Innovation with Clinical Confidence
For MicroLight, innovation is meaningful only when it strengthens clinical usability without compromising the principles behind the technology. This philosophy is reflected in the development of the Smart Laser 2.0.
While maintaining the company’s patented 830 nm technology and research supported therapeutic dose, the newer system introduces an improved user interface, programmable treatment cycles, extended battery life, and greater clinical flexibility. These enhancements are designed to help healthcare professionals integrate laser therapy more efficiently into their existing workflows while maintaining the same underlying therapeutic approach.
Quality assurance is equally important. MicroLight focuses on precise wavelength delivery, controlled therapeutic output, consistency, reliability, and regulatory compliance throughout product development and manufacturing. The objective is to provide clinicians with dependable medical technology that performs according to established specifications.
The company’s evidence based philosophy also extends to clinician education. MicroLight works to address misconceptions surrounding laser therapy, particularly the assumption that all devices produce equivalent clinical results or that higher wattage automatically delivers better outcomes. Through education based on published research and clinical experience, the company encourages healthcare professionals to consider wavelength, therapeutic dose, and treatment protocols when evaluating laser therapy technology.
Supporting the Future of Non Invasive Care
MicroLight’s relationship with healthcare professionals extends beyond the device itself. The company provides product training, treatment protocols, technical assistance, and customer support to help clinicians successfully incorporate its technology into patient care.
Its Medical Advisory Board adds another layer of clinical expertise. Comprised of healthcare professionals who use the Smart Laser in their own practices, the board provides practical insights, answers clinical questions, and shares experience surrounding treatment protocols and applications.
Looking ahead, MicroLight plans to expand awareness and adoption of evidence based Low Level Laser Therapy while strengthening research collaborations, expanding its Medical Advisory Board, and increasing education across additional healthcare specialties. As healthcare continues moving toward non invasive and drug free treatment approaches, the company believes photobiomodulation will continue gaining clinical recognition.
For MicroLight, the future is not about following every emerging trend. It is about continuing to build on the research, clinical validation, and therapeutic principles that have guided the company since 1990. By combining established 830 nm technology, continued product development, clinical education, and long term customer support, MicroLight continues to advance the role of Low Level Laser Therapy in modern healthcare.
